DaVita Inc. stocks have been trading up by 23.46 percent following highly favorable coverage of its earnings outlook.
Click Here for a Millionaire's POV on Trading DVA
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Q1 2026 earnings from DaVita crushed expectations, with EPS of $2.87 versus $2.33 and revenue of $3.42B versus $3.36B.
- Year over year, DaVita’s EPS jumped 43.5% while revenue grew 6%, margins expanded, and dialysis volume headwinds were absorbed.
- Management raised FY26 adjusted EPS guidance to $14.10–$15.20, with the midpoint now above the $14.12–$14.17 Street range.
- Free cash flow swung positive in Q1, and DaVita reaffirmed strong FCF targets that support buybacks and other shareholder returns.
- The company’s medical information chief highlighted AI tools as a way to ease clinician workload and deepen patient relationships, not replace doctors.
Live Update At 16:01:47 EDT: On Wednesday, May 06, 2026 DaVita Inc. stock [NYSE: DVA] is trending up by 23.46%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
DVA just delivered the kind of quarter that wakes up every momentum trader. On 2026/05/05, DaVita posted Q1 EPS of $2.87, smashing the $2.33 consensus, on revenue of $3.42B versus $3.36B expected. That is not a small beat; it is a clear sign the dialysis giant is executing.
Year over year, DaVita’s EPS jumped 43.5% while revenue climbed 6%. Higher reimbursement rates and share buybacks drove much of that EPS surge, even as dialysis volume stayed soft. For traders, that combination says DVA is leveraging pricing, mix, and capital returns to keep the earnings trend pointed up.
On the tape, the market responded fast. DVA closed at $157.04 on 2026/05/05 and then ripped to a $193.88 close on 2026/05/06 after spiking intraday to $194.29. That is a near-25% two‑day swing from the 04/17–04/30 base in the high‑$140s to low‑$150s.
More Breaking News
- BBAI Stock Climbs As Defense AI Growth Story Builds
- UCTT Stock Rallies As Analysts Hike Price Targets On AI Upswing
- DaVita Stock Jumps As Earnings Beat Fuels Bullish Outlook
- MARA Stock Jumps As Long Ridge Deal Reshapes Growth Story
Underneath the price action, DaVita’s fundamentals look solid. Operating cash flow came in at about $320.8M for the quarter, with free cash flow of roughly $218.8M, and the company is trading at a P/E near 15.7 and a low price‑to‑sales of about 0.74.
Why Traders Are Watching DVA Now
When a slow‑and‑steady healthcare name like DVA trades like a high‑beta momentum play, traders take notice. This Q1 print was that kind of catalyst. DaVita did not just beat on EPS and revenue; it showed the quality behind the numbers. Margins improved, free cash flow turned positive, and management felt confident enough to lift 2026 adjusted EPS guidance to $14.10–$15.20, with the midpoint now above consensus. That guidance bump is a clear signal: the team thinks this earnings strength is sustainable, not a one‑off.
Look at the daily chart. DVA spent most of April grinding between roughly $147 and $155, a tight consolidation after a prior run. Then the 2026/05/05 earnings after the close set up a textbook gap‑and‑go. On 2026/05/06, the stock opened at $169.28, ripped through $180 by 09:30–09:40, and kept stair‑stepping higher into the close near $194. Intraday, the five‑minute chart shows controlled pullbacks, higher lows, and support building around the high‑$180s and low‑$190s all afternoon. That’s strong hands buying dips, not bailing.
For swing traders, this move caps a clean breakout from the mid‑$150s with volume and news behind it. For short‑term players, DVA becomes a watch‑list name for sympathy moves whenever healthcare reimbursement, AI in medicine, or large‑cap value momentum trends hit the headlines. With a P/E still under many growth names and a price‑to‑cash‑flow under 5, DVA is not trading like a frothy story stock despite this spike.
On the strategic side, DaVita’s push into AI‑enabled nephrology also matters. The company’s chief medical information officer is framing AI as a tool to cut clinician cognitive load, connect data streams, and strengthen long‑term patient relationships. For the long‑term business, that can mean better outcomes, lower errors, and more efficient clinics—fuel for margin support that the market is starting to price in.
Conclusion
For active traders, DVA is a great case study in how fundamentals and tape can line up. DaVita delivered a clean Q1 2026 beat: EPS way ahead of forecasts, revenue above expectations, margins up, and free cash flow firmly positive. Management backed it up with higher full‑year EPS guidance and reiterated strong cash generation aims that support continued buybacks. The balance sheet still carries heavy long‑term debt, but DaVita’s current ratio near 1.3 and consistent operating cash flow give it room to manage that load.
Short term, the question is simple: does DVA consolidate above the prior $150–$160 zone and build a new base closer to $185–$195, or does it retrace part of this post‑earnings surge? The five‑minute action around $188–$192 showed buyers defending dips, which day traders can use as a reference band. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” That mindset lines up with using these intraday levels and recent price action as a trading roadmap rather than guessing where DVA might be months from now. Longer‑horizon traders will watch whether DaVita’s 0.8 asset‑turnover and high EBIT margins near 19.4% stay intact as reimbursement and volume trends evolve.
The AI narrative adds an extra tailwind. DaVita is not pitching robots to replace doctors; it is using AI to make nephrologists more effective. That kind of story tends to age well in defensive healthcare. As Tim Sykes likes to remind his students, “The market rewards preparation, not hope—study the catalyst, study the chart, and trade the plan.” For DVA, the catalyst is clear, the chart is live, and the homework is up to you.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.